861 related articles for article (PubMed ID: 17110217)
1. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
Olsen EA; Hordinsky M; Whiting D; Stough D; Hobbs S; Ellis ML; Wilson T; Rittmaster RS;
J Am Acad Dermatol; 2006 Dec; 55(6):1014-23. PubMed ID: 17110217
[TBL] [Abstract][Full Text] [Related]
2. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.
Gubelin Harcha W; Barboza Martínez J; Tsai TF; Katsuoka K; Kawashima M; Tsuboi R; Barnes A; Ferron-Brady G; Chetty D
J Am Acad Dermatol; 2014 Mar; 70(3):489-498.e3. PubMed ID: 24411083
[TBL] [Abstract][Full Text] [Related]
3. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss.
Roberts JL; Fiedler V; Imperato-McGinley J; Whiting D; Olsen E; Shupack J; Stough D; DeVillez R; Rietschel R; Savin R; Bergfeld W; Swinehart J; Funicella T; Hordinsky M; Lowe N; Katz I; Lucky A; Drake L; Price VH; Weiss D; Whitmore E; Millikan L; Muller S; Gencheff C
J Am Acad Dermatol; 1999 Oct; 41(4):555-63. PubMed ID: 10495375
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study.
Eun HC; Kwon OS; Yeon JH; Shin HS; Kim BY; Ro BI; Cho HK; Sim WY; Lew BL; Lee WS; Park HY; Hong SP; Ji JH
J Am Acad Dermatol; 2010 Aug; 63(2):252-8. PubMed ID: 20605255
[TBL] [Abstract][Full Text] [Related]
5. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
Drake L; Hordinsky M; Fiedler V; Swinehart J; Unger WP; Cotterill PC; Thiboutot DM; Lowe N; Jacobson C; Whiting D; Stieglitz S; Kraus SJ; Griffin EI; Weiss D; Carrington P; Gencheff C; Cole GW; Pariser DM; Epstein ES; Tanaka W; Dallob A; Vandormael K; Geissler L; Waldstreicher J
J Am Acad Dermatol; 1999 Oct; 41(4):550-4. PubMed ID: 10495374
[TBL] [Abstract][Full Text] [Related]
6. Finasteride in the treatment of Japanese men with male pattern hair loss.
Kawashima M; Hayashi N; Igarashi A; Kitahara H; Maeguchi M; Mizuno A; Murata Y; Nogita T; Toda K; Tsuboi R; Ueki R; Yamada M; Yamazaki M; Matsuda T; Natsumeda Y; Takahashi K; Harada S
Eur J Dermatol; 2004; 14(4):247-54. PubMed ID: 15319158
[TBL] [Abstract][Full Text] [Related]
7. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia.
Finasteride Male Pattern Hair Loss Study Group
Eur J Dermatol; 2002; 12(1):38-49. PubMed ID: 11809594
[TBL] [Abstract][Full Text] [Related]
8. Dutasteride improves male pattern hair loss in a randomized study in identical twins.
Stough D
J Cosmet Dermatol; 2007 Mar; 6(1):9-13. PubMed ID: 17348989
[TBL] [Abstract][Full Text] [Related]
9. Effective treatment of female androgenic alopecia with dutasteride.
Olszewska M; Rudnicka L
J Drugs Dermatol; 2005; 4(5):637-40. PubMed ID: 16167423
[TBL] [Abstract][Full Text] [Related]
10. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
11. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.
Price VH; Roberts JL; Hordinsky M; Olsen EA; Savin R; Bergfeld W; Fiedler V; Lucky A; Whiting DA; Pappas F; Culbertson J; Kotey P; Meehan A; Waldstreicher J
J Am Acad Dermatol; 2000 Nov; 43(5 Pt 1):768-76. PubMed ID: 11050579
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
13. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M; Fleshner NE; Finelli A; Zlotta AR
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
[TBL] [Abstract][Full Text] [Related]
14. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
[TBL] [Abstract][Full Text] [Related]
15. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration.
Ryu HK; Kim KM; Yoo EA; Sim WY; Chung BC
Br J Dermatol; 2006 Apr; 154(4):730-4. PubMed ID: 16536818
[TBL] [Abstract][Full Text] [Related]
17. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Andriole GL; Humphrey P; Ray P; Gleave ME; Trachtenberg J; Thomas LN; Lazier CB; Rittmaster RS
J Urol; 2004 Sep; 172(3):915-9. PubMed ID: 15310997
[TBL] [Abstract][Full Text] [Related]
18. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
19. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
[TBL] [Abstract][Full Text] [Related]
20. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old.
Camacho FM; García-Hernández MJ; Fernández-Crehuet JL
Br J Dermatol; 2008 May; 158(5):1121-4. PubMed ID: 18363752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
